Concepedia

Yasaman Barekatain

YB

10

Publications

437

Citations

10

H-Index

2020

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

The University of Texas Health Science Center at Houston

Beth Israel Deaconess Medical Center

Harvard University

Washington University in St. Louis

Yasaman Barekatain is an author at The University of Texas MD Anderson Cancer Center specializing in cancer research, medicine, and cell biology.

ORCID

Top concepts

Publications per year

2020–2023

10

Publications

10

KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells

Krishnan K. Mahadevan, Kathleen M. McAndrews, Valerie S. LeBleu et al. · Cancer Cell · 2023 · 193 citations · Full text

, , +11

An enolase inhibitor for the targeted treatment of ENO1-deleted cancers

Yu-Hsi Lin, Nikunj Satani, Naima Hammoudi et al. · Nature Metabolism · 2020 · 95 citations · Full text

, , +5

Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine

Yasaman Barekatain, Jeffrey J. Ackroyd, Victoria C. Yan et al. · Nature Communications · 2021 · 49 citations · Full text

Impaired anaplerosis is a major contributor to glycolysis inhibitor toxicity in glioma

Sunada Khadka, Kenisha Arthur, Yasaman Barekatain et al. · Cancer & Metabolism · 2021 · 22 citations · Full text

Targeting Host Glycolysis as a Strategy for Antimalarial Development

Andrew J. Jezewski, Yu-Hsi Lin, Julie A. Reisz et al. · Frontiers in Cellular and Infection Microbiology · 2021 · 19 citations · Full text

Rows per page

1–5 of 10